Supernus Pharmaceuticals Inc (SUPN)

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Supernus Pharmaceuticals to Participate in June Investor Conferences

ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a...

Form 8-K - Current report

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Supernus Announces First Quarter 2026 Financial Results

Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026

ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a...